

**CODING FORMS FOR SRC INDEXING**

<b>Microfiche No.</b>		
OTS0559991		
<b>New Doc</b>		<b>Old Doc ID</b>
88010000059		8EHQ-0101-14847
<b>Date Produced</b>	<b>Date Received</b>	<b>TSCA Section</b>
01/08/01	01/09/01	8E
<b>Submitting Organization</b>		
E I DUPONT DE NEMOURS & CO		
<b>Contractor</b>		
<b>Document Title</b>		
INITIAL SUBMISSION: LETTER FROM E I DUPONT DE NEMOURS & CO REPORTING RESULTS OF ORAL RANGE-FINDING STUDY IN RATS WITH CIS-2-PENTENENITRILE, DATED 1/8/2001		
<b>Chemical Category</b>		
CIS-2-PENTENENITRILE		

A 03

**BEHQ-0101-14847**

DuPont Haskell Laboratory  
for Toxicology and Industrial Medicine  
Elkton Road, P.O. Box 50  
Newark, DE 19714-0050



RECEIVED  
OPPT CBIC

DuPont Haskell Laboratory

2001 JAN -9 AM 11:35

MA 42830

January 8, 2001



**BEHQ-01-14847**

Via Federal Express

Document Processing Center (7407)  
Room G99 East Tower  
Attention: 8(e) Coordinator  
Office of Pollution Prevention and Toxics  
U.S. Environmental Protection Agency  
401 M Street SW  
Washington, D.C. 20460-0001.

**Contain NO CBI**

Dear 8(e) Coordinator:

Cis-2-Pentenenitrile  
[CAS # 25899-50-7]



**88010000059**

2001 JAN 17 AM 8:30

RECEIVED  
OPPT CBIC

This letter is to inform you of the results of a recently conducted oral range-finding study in rats with the above referenced test substance.

Groups of young, adult male and female CrI:CD® (IGS)BR rats (5/sex/dose) were administered by oral gavage, doses of 0, 1, 10, 30, 100, or 150 mg/kg/day of the test substance for 7 days. Rats were held for an additional 14-day recovery period. The rats were evaluated for body weight changes, food consumption, and clinical signs of toxicity. A functional observational battery (FOB) and motor activity assessment were performed at the end of the dosing period and after the 14-day recovery phase of the study. Rats were sacrificed at the end of the recovery phase and evaluated for gross pathology.

Male and/or female rats dosed at 100 and/or 150 mg/kg/day showed clinical signs that included reduced body weight and nutritional parameters, cloudy eyes, abnormal gait, tremors, high arousal, exaggerated response to tail pinch, increased vocalization, high carriage, splayed limbs, reduced motor activity, head tilt and hyper-reactivity. One female rat dosed at 30 mg/kg/day had cloudy eyes only at the end of the recovery phase. Most effects were partially or completely reversible during the recovery phase. Eyes were still cloudy in affected groups, although less severe, and motor activity was still reduced in the males administered 150 mg/kg/day.

**A 04**

Under these experimental conditions, the findings described above appear to be reportable based upon guidance given in the EPA TSCA Section 8(e) Reporting Guide (June 1991).

Sincerely,

A handwritten signature in black ink that reads "A. Michael Kaplan". The signature is written in a cursive style with a long horizontal flourish extending to the right.

A Michael Kaplan, Ph.D.  
Director – Regulatory Affairs

AMK/SAM:clp  
(302) 366-5260